tizanidine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 36 Diseases   20 Trials   20 Trials   376 News 


«12345
  • ||||||||||  Intrathecal Baclofen Patient Activated Bolus Device for Treatment-Resistant Stiff-Person: A Case Report () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_1115;    
    Seven years after onset of symptoms, he was diagnosed with Stiff-Person Syndrome by an outside provider and treated with oral Baclofen, Gabapentin, Tizanidine and IVIG without significant improvement...For severe or refractory disease, other therapies such as rituximab, plasma exchange, spinal cord stimulation for painful muscle spasms, botulinum toxin and anticonvulstants.There have been case reports of the efficacy of intrathecal baclofen therapy for SPS but none that utilized a patient activated bolus device...It is important to treat SPS symptoms early to improve patient function and quality of life. This case highlights the potential for Intrathecal Baclofen to significantly improve the quality of life in those patients with SPS by using a Patient Activated Bolus Device.
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Drug-induced Sweet’s syndrome initially presenting as Stevens-Johnson syndrome in the Acute Rehabilitation setting () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_780;    
    Dermatology performed a punch biopsy and recommended Etanercept for a suspected Stevens-Johnson syndrome...Conclusions : Drug-induced Sweet’s syndrome is a rare illness that may initially present as Stevens-Johnson syndrome and can be caused by various drugs such as Celecoxib which was the presumptive etiology in this case. Early detection, prompt withdrawal of offending agent and corticosteroid treatment is vital as pain/discomfort poses a barrier to a patient’s acute rehabilitation course.
  • ||||||||||  baclofen / Generic mfg., tizanidine / Generic mfg.
    Anoxic Brain Injury with Dystonia and Spasticity () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_485;    
    Conclusions : Neurologic complications of anoxic brain injury such as rigidity and dystonia improve significantly through interdisciplinary rehabilitation. We need to rethink current practices to include use of carbidopa-levodopa for atypical parkinsonian features post anoxic injury and use of early intrathecal baclofen pump placement to improve patient’s functional status and quality of life.
  • ||||||||||  tizanidine / Teva, LFB Biotechnologies
    Preclinical, Journal:  Development of thiomer based buccal films for the enhancement of bioavailability: An in-vivo analysis. (Pubmed Central) -  Dec 6, 2019   
    Present work was conducted to improve the bioavailability of Tizanidine HCl (TZN) by formulating mucoadhesive buccal films (MBFs) using novel thiolated arabinoxylan (TAX) as film former...Results have explored that, t1/2 was increased from 2.51hrs (SOS) to 10 hrs, C from 42.3 ng/ml (SOS) to 105ng/ml and t from 2hrs (SOS) to 6h. Conclusively, TAX has exhibited the potential to form MBFs thereby offering sustained release of TZN with improved pharmacokinetic profile.
  • ||||||||||  Northera (droxidopa) / Lundbeck, Sumitomo Dainippon, sildenafil / Generic Mfg., tizanidine / Teva, LFB Biotechnologies
    Clinical, Journal:  Orthostatic Hypotension in the Hypertensive Patient. (Pubmed Central) -  Nov 14, 2019   
    OH and postprandial hypotension can be prevented with abdominal binders and acarbose, respectively, without the need to increase baseline blood pressure...If traditional pressor agents are needed, midodrine and droxidopa can be used, administered at the lowest dose and frequency that improves symptoms. Management of OH in the hypertensive patient is challenging, but a management strategy based on understanding the underlying pathophysiology can be effective in most patients.
  • ||||||||||  Journal:  Non-medical use of psychoactive prescription drugs is associated with fatal poisoning. (Pubmed Central) -  Oct 19, 2019   
    Management of OH in the hypertensive patient is challenging, but a management strategy based on understanding the underlying pathophysiology can be effective in most patients. Non-prescribed psychoactive drugs are commonly found at post-mortem in drug poisoning deaths in Finland with history of drug abuse being a major contributing factor.
  • ||||||||||  Pharmacotherapies Targeting Type 2 SLE Symptoms (Hall B5) -  Oct 7, 2019 - Abstract #ACRARHP2019ACR_3557;    
    Patients with active Type 2 SLE are differentially prescribed SNRIs, gabapentinoids, and muscle relaxers. Corticosteroids are more often prescribed to address active Type 1 rather than Type 2 activity and are not associated with Type 2 symptom severity.
  • ||||||||||  Case #1: multimodal management of spasticity (Meeting Room T3) -  Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_43;    
    Antispasticity drugs (baclofen, tizanidine) may be offered in cases with functionally relevant spasticity but care should be taken with regard to side effects (weakness, loss of standing and walking, increasing fatigue)...Paroxysmal spasms may be ameliorated with gabapentin. The symptomatic treatment of MS-related spasticity includes pharmacological and non-pharmacological measures that should be goal-oriented and tailored towards the need and expectations of the individual patient.
  • ||||||||||  dronabinol / generics
    Journal:  A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis. (Pubmed Central) -  Jun 22, 2019   
    ...The roles of oral and intrathecal baclofen and of delta-9-tetrahydrocannabinol/cannabidiol (THC:CBD) oromucosal spray in treating MS spasticity-related gait impairment are reviewed...Oral baclofen and tizanidine are generally used for first-line treatment of MS spasticity but are ineffective in approximately 40% of cases...In studies of patients with resistant MS spasticity, THC:CBD spray consistently improved the timed 10-meter walk test and significantly improved multiple spatial-temporal and kinematic gait parameters. THC:CBD oromucosal spray warrants further investigation as a treatment for MS spasticity-related gait impairment.
  • ||||||||||  tizanidine / Teva, LFB Biotechnologies
    Review, Journal:  A systematic review of using myorelaxants in treatment of low back pain (Pubmed Central) -  May 31, 2019   
    2017. The authors conclude that there are enough data to confirm the efficacy of myorelaxants in treatment of nonspecific low back pain, myorelaxants are recommended as monotherapy or in combination with analgesics or NSAID, the nonsedative drugs tolperisone or thiocolchicoside should be preferred.
  • ||||||||||  baclofen / Generic mfg., tizanidine / Generic mfg., ibuprofen / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain (clinicaltrials.gov) -  Nov 8, 2018   
    P4,  N=320, Completed, 
    This case suggests that tizanidine should be used cautiously when combined with loxoprofen, and drug interaction screening should be performed. Recruiting --> Completed | Trial completion date: Jun 2019 --> Oct 2018 | Trial primary completion date: Mar 2019 --> Jul 2018
  • ||||||||||  Trial completion, Enrollment change:  Prospective Analgesic Compound Efficacy (PACE) Study (clinicaltrials.gov) -  Feb 1, 2018   
    P=N/A,  N=300, Completed, 
    Recruiting --> Completed | Trial completion date: Jun 2019 --> Oct 2018 | Trial primary completion date: Mar 2019 --> Jul 2018 Enrolling by invitation --> Completed | N=500 --> 300
  • ||||||||||  tizanidine / Generic mfg.
    Enrollment change, Trial withdrawal:  Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain (clinicaltrials.gov) -  Dec 15, 2017   
    P2,  N=0, Withdrawn, 
    Enrolling by invitation --> Completed | N=500 --> 300 N=400 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  baclofen / Generic mfg., tizanidine / Generic mfg., ibuprofen / Generic mfg.
    Enrollment open:  Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain (clinicaltrials.gov) -  May 5, 2017   
    P4,  N=320, Recruiting, 
    N=400 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
  • ||||||||||  Enrollment open:  Prospective Analgesic Compound Efficacy (PACE) Study (clinicaltrials.gov) -  Jan 21, 2016   
    P=N/A,  N=500, Enrolling by invitation, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
  • ||||||||||  tizanidine / Generic mfg.
    Enrollment change:  Tizanidine and Pain After Herniorrhaphy (clinicaltrials.gov) -  Dec 10, 2014   
    P4,  N=30, Completed, 
    Recruiting --> Completed | N=32 --> 18 | Trial primary completion date: Feb 2015 --> Aug 2014 N=40 --> 30
  • ||||||||||  tizanidine / Generic mfg.
    Trial completion, Trial primary completion date:  Tizanidine and Pain After Herniorrhaphy (clinicaltrials.gov) -  Sep 10, 2014   
    P4,  N=40, Completed, 
    N=40 --> 30 Recruiting --> Completed | Trial primary completion date: Mar 2014 --> Jun 2014
  • ||||||||||  tizanidine / Generic mfg.
    New P4 trial:  Tizanidine and Pain After Herniorrhaphy (clinicaltrials.gov) -  Dec 18, 2013   
    P4,  N=40, Recruiting, 
  • ||||||||||  verapamil / Generic mfg., nifedipine immediate release / Generic mfg., tizanidine / Generic mfg.
    Enrollment change:  OMDD3: Drug Discrimination in Methadone-Maintained Humans Study 3 (clinicaltrials.gov) -  Mar 5, 2013   
    P1,  N=9, Completed, 
    Not yet recruiting --> Recruiting N=40 --> 9
  • ||||||||||  verapamil / Generic mfg., nifedipine immediate release / Generic mfg., tizanidine / Generic mfg.
    Trial completion:  OMDD3: Drug Discrimination in Methadone-Maintained Humans Study 3 (clinicaltrials.gov) -  Mar 5, 2013   
    P1,  N=9, Completed, 
    N=40 --> 9 Recruiting --> Completed
  • ||||||||||  tizanidine / Generic mfg.
    Trial termination:  Phase 1b Study of Tizanidine in Pediatric Patients With Cerebral Palsy (clinicaltrials.gov) -  Apr 26, 2012   
    P1,  N=10, Terminated, 
    Recruiting --> Completed Recruiting --> Terminated; Please see 'Further study details as provided by Acorda Therapeutics' for explanation of why study stopped.